The performance of constituent stocks was excellent. The medical and American sector swept away the "haze" of policy and rebounded violently for three consecutive days!
On October 13, Yimei concept stocks strengthened again, blonde Rabbi rose by the limit, Langzi shares and Aoyuan Meigu rose by more than 8%, followed by Yuexin health, Aoyang health, betaine and Aibo medical.
It is worth noting that Langzi shares in medical beauty concept stocks have been trading for three consecutive days, with a cumulative increase of 39% since October 8. Just yesterday, on October 12, Langzi released the performance forecast for the third quarter of 2021. The company expects to achieve a net profit of 147-165 million yuan in the first three quarters, a year-on-year increase of 194.04% - 230.04%; The net profit in the third quarter was 53.6831 million yuan - 71.6831 million yuan, a year-on-year increase of 1.54% - 35.58%.
Compared with the company's performance in the first half of the year, the company's performance growth slowed down in the three quarter, which was mainly affected by the cardinal effect. In the first half of 2020, the high-end women's clothing business was greatly influenced by COVID-19 and the low base effect was more significant. In the second half of the year, with the gradual elimination of the epidemic situation and the gradual recovery of high-end women's clothing, the company's performance in 2020 was lower and higher.
Excluding the influence of the above women's wear business, the company's medical beauty business developed smoothly. In the first three quarters, the company opened three new crystal skin light medical beauty institutions, and the number continued to expand. Guojin Securities said that it is expected that the number of stores opened by the company will continue to rise in the fourth quarter of 2021; It is expected that the revenue of 3q2021 medical beauty business will maintain rapid growth. According to the new and old institutions, the old institutions are expected to contribute to the main performance. The new institutions are still in the cultivation period, which has a drag on the overall profitability of medical beauty business. It is expected that the net interest rate of the company's medical beauty in the reporting period will decrease compared with the first half of the year.
In the medical and beauty sector, not only is Langzi a company with excellent performance, but Aoyuan Meigu also released 3q2021 performance forecast on October 12. The forecast shows that during the reporting period, the company is expected to realize a net profit attributable to the parent company of RMB 200-250 million, with a year-on-year increase of 308% - 360%, and turn losses into profits. Looking at Q3 alone, the net profit attributable to the parent company is expected to be 150-200 million yuan, an increase of 55-107% over the same period last year, and the performance significantly exceeded the market expectation.
In fact, the performance of the medical beauty sector has always been online. Several leaders of the medical beauty sector led by Aimeike and Huaxi biology have shown good strength in the semi annual report. However, under the strong pressure of policies, the investor's mood is more pessimistic, and there is a certain correction in the sector.
In July, affected by the "double reduction" policy of the education industry, medical beauty, as one of the industries with savage growth in recent years, was recognized by investors as the direction of the next policy. From July 22 to July 27, the wind medical beauty index fell by 16.43%.
In August, the policy came as scheduled, but there was no correction in the medical and American sector. On August 27, in order to improve the scientificity and standardization of the regulatory rules for medical beauty advertising and safeguard the legitimate rights and interests of consumers, the General Administration of market supervision studied and drafted the law enforcement guide for medical beauty advertising (Draft for comments) in accordance with the advertising law, medical advertising management measures and other laws, regulations and rules, and now solicits opinions from the public.
Zhongtai Securities believes that the policy of the medical and American industry is becoming stricter, which is conducive to the long-term development of the industry. Although, in the short term, it may cause pain for relevant platforms and medium and low-end products, in the long term, it is expected to improve the industry concentration, benefit the industry leaders and enhance the brand power.